Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$8.44 +2.4%	$10.02	$6.65 ▼ $58.24	$4.72M	1.14	9,458 shs	5,507 shs
PCSA Heatwurx	$0.23 +3.3%	$0.24	$0.15 ▼ $1.58	$2.62M	1.32	5.93 million shs	5.19 million shs
PXMD PaxMedica	$0.00	$0.00	$0.00 ▼ $0.26	$2K	-0.99	11,822 shs	N/A
VBLT Vascular Biogenics		$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	+5.64%	+7.01%	-31.33%	-30.53%	-82.79%
PCSA Heatwurx	-1.03%	-8.80%	-2.43%	-5.68%	-84.88%
PXMD PaxMedica	0.00%	0.00%	+100.00%	+100.00%	-99.91%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INDP Indaptus Therapeutics	3.2076 of 5 stars	3.5	5.0	0.0	0.0	1.0	1.7	1.3
PCSA Heatwurx	2.3352 of 5 stars	3.5	2.0	0.0	0.0	0.9	1.7	1.3
PXMD PaxMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INDP Indaptus Therapeutics	3.00	Buy	$238.00	2,719.91% Upside
PCSA Heatwurx	3.00	Buy	$2.00	777.19% Upside
PXMD PaxMedica	0.00	N/A	N/A	N/A
VBLT Vascular Biogenics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INDP, PCSA, VBLT, and PXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$10.84 per share	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.51 per share	N/A
PXMD PaxMedica	N/A	N/A	N/A	N/A	$0.46 per share	N/A
VBLT Vascular Biogenics	$660K	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INDP Indaptus Therapeutics	-$15.02M	-$41.74	N/A	N/A	N/A	N/A	-333.02%	-216.36%	N/A
PCSA Heatwurx	-$11.85M	-$2.32	N/A	N/A	N/A	N/A	-342.36%	-243.48%	10/29/2025 (Estimated)
PXMD PaxMedica	-$18.29M	N/A	0.00	∞	N/A	N/A	-3,167.89%	-560.35%	N/A
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	N/A	N/A	N/A	-73.45%	-54.11%	N/A

Latest INDP, PCSA, VBLT, and PXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
5/14/2025	Q1 2025	INDP Indaptus Therapeutics	-$11.48	-$8.96	+$2.52	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
PXMD PaxMedica	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INDP Indaptus Therapeutics	N/A	1.90	1.90
PCSA Heatwurx	N/A	3.45	3.45
PXMD PaxMedica	N/A	0.38	0.38
VBLT Vascular Biogenics	N/A	4.63	4.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INDP Indaptus Therapeutics	7.06%
PCSA Heatwurx	91.93%
PXMD PaxMedica	4.90%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
INDP Indaptus Therapeutics	20.80%
PCSA Heatwurx	9.60%
PXMD PaxMedica	1.00%
VBLT Vascular Biogenics	6.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INDP Indaptus Therapeutics	6	570,000	454,000	Not Optionable
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
PXMD PaxMedica	2	11.31 million	11.20 million	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

INDP, PCSA, VBLT, and PXMD Headlines

Recent News About These Companies

VBL warns of financial impact of severance payments in second pillar reform

September 4, 2024 | ipe.comI

Market Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%

July 30, 2024 | msn.com

Tom Sox move one step closer to VBL title with 7-5 win over Purcellville

July 30, 2024 | cbs19news.comC

Tom Sox drop game one of the VBL South Division Series against Cavaliers, 4-1

July 26, 2024 | cbs19news.comC

Benign and Malignant Vascular Tumors of the Liver in Adults

May 23, 2024 | medscape.comM

VBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To Come

May 14, 2024 | msn.com

AlboGraft Polyester Vascular Graft from LeMaitre

May 7, 2024 | news-medical.netN

Tommy Garten elected to VBL Hall of Fame

March 28, 2024 | therecorderonline.comT

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

February 21, 2024 | nature.comN

Vascular News and Research

November 25, 2023 | news-medical.netN

Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26

November 2, 2023 | msn.com

Notable Labs Closes Merger Transaction With VBL Therapeutics

October 16, 2023 | finance.yahoo.com

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

October 12, 2023 | finance.yahoo.com

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

October 4, 2023 | finance.yahoo.com

Vascular Biogenics Rises on Presentation Hype

September 9, 2023 | finance.yahoo.com

VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days

September 7, 2023 | knoxdaily.comK

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

September 6, 2023 | finance.yahoo.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023 | businesswire.com

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT

August 28, 2023 | businesswire.com

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 14, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP, PCSA, VBLT, and PXMD Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

$8.44 +0.20 (+2.43%)

Closing price 03:57 PM Eastern

Extended Trading

$8.08 -0.36 (-4.27%)

As of 07:48 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Heatwurx NASDAQ:PCSA

$0.23 +0.01 (+3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$0.23 +0.00 (+0.44%)

As of 07:59 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

PaxMedica NASDAQ:PXMD

$0.0002 0.00 (0.00%)

As of 08/12/2025

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Vascular Biogenics NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time